Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Legal Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,793 |
Ending reported balance
After 2026-09-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-11 · Grant · Acquired 4,483 · Balance 59,212 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Row 2 · 2026-09-11 · Tax withholding · Disposed 2,419 · Balance 56,793 F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2019 Filed Sep 5, 2019 20:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,736 | $100.00 | $673,600.00 |
DisclosureSEC source: 0001209191-19-048482 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,103 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 20:09 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 6,736 | $32.99 | $222,220.64 |
DisclosureSEC source: 0001209191-19-048482 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 142 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on August 30, 2019. Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,600 | $32.99 Strike: $32.99 | $52,784.00 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · derivative · entry 6 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,361 Underlying: Common Stock · 1,600 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,600 | $100.00 | $160,000.00 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 27, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,600 | $32.99 | $52,784.00 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,664 | $32.99 Strike: $32.99 | $54,895.36 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · derivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,961 Underlying: Common Stock · 1,664 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,664 | $100.09 | $166,554.92 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,664 | $32.99 | $54,895.36 |
DisclosureSEC source: 0001209191-19-047571 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,831 | $18.15 Strike: $18.15 | $287,332.65 |
DisclosureSEC source: 0001209191-19-043918 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,831 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Represents option which vested 1/4 upon anniversary of grant (11/3/2014), thereafter vested in equal monthly installments over the following three years such that the entire award was fully vested at 11/3/2018. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,831 | $92.13 | $1,458,568.60 |
DisclosureSEC source: 0001209191-19-043918 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,961 F2 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.39 to $94.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 23:14 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,831 | $18.15 | $287,332.65 |
DisclosureSEC source: 0001209191-19-043918 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 315 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2019. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 11,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008639 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,567 Underlying: Common Stock · 11,567 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. F5 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 7, 2020, February 7, 2021, February 7, 2022, and February 7, 2023. Read SEC document |
| February 07, 2019 Filed Feb 8, 2019 22:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 62,506 | $0.00 Strike: $81.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008639 · doc4.xml · derivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,506 Underlying: Common Stock · 62,506 shares Expires 2029-02-07 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 7, 2019 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:10 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 791 | $83.52 | $66,063.37 |
DisclosureSEC source: 0001209191-19-008639 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,646 F1 · kind: Sale of 791 shares of common stock issued upon vesting of 2,275 restricted stock units on February 6, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,484) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $80.79 to $85.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 23:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 470 | $88.11 | $41,409.49 |
DisclosureSEC source: 0001209191-19-007852 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,162 F3 · kind: Sale of 470 shares of common stock issued upon vesting of 1,150 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (680) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.46 to $88.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2019 Filed Feb 6, 2019 23:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 755 | $88.08 | $66,501.08 |
DisclosureSEC source: 0001209191-19-007852 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,482 F1 · kind: Sale of 755 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2019 to cover payroll and withholding taxes, with the balance of the shares (1,420) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $87.46 to $88.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,979 | $18.15 Strike: $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-017715 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,831 Underlying: Common Stock · 1,979 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,979 | $88.47 | $175,089.65 |
DisclosureSEC source: 0001209191-18-017715 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,062 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $85.27 to $90.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,979 | $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-017715 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 787 | $82.48 | $64,911.76 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 4 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,062 F5 · kind: Payment of tax liability by withholding 787 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,488) maintained by the Reporting Person. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 12,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 8 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2021-03-15 F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F10 · derivative.exercise_date: A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 7 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 26,050 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 6 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,050 Underlying: Common Stock · 26,050 shares Expires 2028-02-05 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,979 | $18.15 Strike: $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · derivative · entry 5 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Common Stock · 1,979 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 758 | $83.13 | $63,012.16 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,574 F3 · kind: Sale of 758 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,417) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.64. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,979 | $83.11 | $164,482.21 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.20 to $84.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 23:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,979 | $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-008215 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 1,979 | $18.15 Strike: $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,789 Underlying: Common Stock · 1,979 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,979 | $79.36 | $157,053.44 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| January 03, 2018 Filed Jan 4, 2018 21:07 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,979 | $18.15 | $35,918.85 |
DisclosureSEC source: 0001209191-18-001899 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,237 | $18.15 Strike: $18.15 | $276,551.55 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,768 Underlying: Common Stock · 15,237 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 15,237 | $75.00 | $1,142,775.00 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| December 28, 2017 Filed Jan 2, 2018 21:02 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,237 | $18.15 | $276,551.55 |
DisclosureSEC source: 0001209191-18-000156 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 2,955 | $18.15 Strike: $18.15 | $53,633.25 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,005 Underlying: Common Stock · 2,955 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4th upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 2,955 | $75.00 | $221,625.00 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| December 08, 2017 Filed Dec 11, 2017 21:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,955 | $18.15 | $53,633.25 |
DisclosureSEC source: 0001209191-17-065019 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 6,279 | $18.15 Strike: $18.15 | $113,963.85 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,960 Underlying: Common Stock · 6,279 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 6,279 | $75.04 | $471,159.83 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 6,279 | $18.15 | $113,963.85 |
DisclosureSEC source: 0001209191-17-064210 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-qualified Stock Option · Derivative | 9,900 | $18.15 Strike: $18.15 | $179,685.00 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,492 Underlying: Common Stock · 9,900 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/03/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/03/2018. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 9,900 | $73.05 | $723,191.04 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $72.50 to $73.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 21:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 9,900 | $18.15 | $179,685.00 |
DisclosureSEC source: 0001209191-17-061486 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 100 | $18.15 Strike: $18.15 | $1,815.00 |
DisclosureSEC source: 0001209191-17-052022 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,139 Underlying: Common Stock · 100 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vested 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 100 | $60.00 | $6,000.00 |
DisclosureSEC source: 0001209191-17-052022 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 18:59 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 100 | $18.15 | $1,815.00 |
DisclosureSEC source: 0001209191-17-052022 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2017 Filed Aug 14, 2017 16:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 5,000 | $18.15 Strike: $18.15 | $90,750.00 |
DisclosureSEC source: 0001209191-17-048697 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,239 Underlying: Common Stock · 5,000 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| August 09, 2017 Filed Aug 14, 2017 16:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 5,000 | $55.00 | $275,000.00 |
DisclosureSEC source: 0001209191-17-048697 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| August 09, 2017 Filed Aug 14, 2017 16:30 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 5,000 | $18.15 | $90,750.00 |
DisclosureSEC source: 0001209191-17-048697 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:34 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 10,000 | $18.15 Strike: $18.15 | $181,500.00 |
DisclosureSEC source: 0001209191-17-034631 · doc4.xml · derivative · entry 3 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,239 Underlying: Common Stock · 10,000 shares Expires 2024-11-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Represents option which vests 1/4 upon anniversary of grant (11/3/2015), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. Read SEC document |
| May 18, 2017 Filed May 23, 2017 20:34 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 10,000 | $53.27 | $532,700.00 |
DisclosureSEC source: 0001209191-17-034631 · doc4.xml · nonDerivative · entry 2 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $52.53 to $53.67. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.